TP53 and neoplasm: In the preplanned subgroup analysis of patients received ET + everolimus (n = 78), the detrimental effect of high tumor burden (HR 1.70, 95% CI 1.04–2.78, p = 0.03) and PIK3CA and/or TP53 oncogenic mutation (HR 1.67, 95% CI 1.02–2.76, p = 0.04) remained significant (Fig. 4b).